Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial

Abstract Background In the GO-VIBRANT trial of intravenous golimumab in psoriatic arthritis (PsA), golimumab significantly inhibited radiographic progression. In post hoc analyses, we evaluated changes in total PsA-modified Sharp/van der Heijde scores (SHS) across levels of composite index-defined d...

Full description

Bibliographic Details
Main Authors: Philip Mease, M. Elaine Husni, Shelly Kafka, Soumya D. Chakravarty, Diane D. Harrison, Kim Hung Lo, Stephen Xu, Elizabeth C. Hsia, Arthur Kavanaugh
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Arthritis Research & Therapy
Subjects:
Psoriatic arthritis
Intravenous golimumab
Anti-TNF therapy
Biologic therapy
Radiographic progression
Composite indices
Online Access:http://link.springer.com/article/10.1186/s13075-020-2126-1

Internet

http://link.springer.com/article/10.1186/s13075-020-2126-1

Similar Items